Flex (NSDQ:FLEX) today announced a partnership with Novo Nordisk (NYSE:NVO) to develop digital diabetes management tools using Flex’s BrightInsight IoT platform.
Novo Nordisk plans to use Flex’s BrightInsight system to build and manage connected medical devices and the corresponding data. The company’s IoT platform is designed to enable organizations to develop digital health devices while remaining compliant with global privacy and security regulations.
“Traditional methods of managing diabetes have not kept pace with a world moving at digital speed,” Dr. Kal Patel, SVP of digital health at Flex, said in prepared remarks. “BrightInsight securely unlocks real-world data and actionable insights, enabling pharma and medtech companies to develop advanced regulated digital health solutions that enable automated clinical decisions and better engagement between clinicians and people with diabetes.”
“Addressing the growing diabetes epidemic takes more than best-in-class medicines alone. We need to engage with people on their level and integrate with the solutions they are already using to manage their diabetes,” Anders Dyhr Toft, corporate VP of commercial innovation at Novo Nordisk, added. “Medical-grade digital health platforms like BrightInsight are key to helping us improve the dialogue between people with diabetes and their caregivers.”
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.